Combined usage of rHVT-H5 and Re-6 vaccines towards an effective avian influenza vaccination program for commercial layer chickens

Md. Zulfekar Ali
{"title":"Combined usage of rHVT-H5 and Re-6 vaccines towards an effective avian influenza vaccination program for commercial layer chickens","authors":"Md. Zulfekar Ali","doi":"10.3329/sjm.v10i1.50725","DOIUrl":null,"url":null,"abstract":"Vaccination against highly pathogenic avian influenza virus (HPAIV) of subtype H5N1 is one of the possible means to protect chickens against its outbreak in endemic countries. Early vaccination of layer birds with recombinant vector vaccine based on turkey herpesvirus expressing H5 gene (rHVT-H5) provides longer protection while inactivated vaccine Re-6 needs multiple booster doses to achieve continuous antibody titer. Therefore, this study was carried out to offer a vaccination program using live rHVT-H5 and inactivated Re-6 vaccines in field condition. For this trial, five ISA brown commercial layer chicken farms were raised with 500 birds per farm. Two licensed vaccines- rHVT-H5 and Re-6 in Bangladesh were used for this trial where birds in farms 1 and 2 were administered only rHVT-H5 vaccine at one-day-old, and farms 3 and 4 rHVT-H5 vaccine at one-day-old then boosted with Re-6 vaccine at 25 weeks of age. Farm 5 was not vaccinated and functioned as control. Blood samples were randomly collected from 20 birds in each farm at 3-week interval from 2 weeks old till 65 weeks and harvested serum analyzed by haemagglutination inhibition (HI) test for antibodies against HPAIV H5N1. The titer of haemagglutination inhibiting antibodies against AIV H5N1 on farms 3 and 4 was considerably high and remained up to 65 weeks. However, in farm 1 and 2 there was decline in antibody titer after 56 weeks of age. This study demonstrated that the combined use of rHVT-H5 vaccine at one-day-old and Re-6 at 25 weeks of age enhanced a longer lasting protective antibody against circulating HPAIV H5N1 in commercial layer chickens in Bangladesh. \nStamford Journal of Microbiology, Vol.10 (1) 2020: 9-11","PeriodicalId":170445,"journal":{"name":"Stamford Journal of Microbiology","volume":"37 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Stamford Journal of Microbiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3329/sjm.v10i1.50725","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Vaccination against highly pathogenic avian influenza virus (HPAIV) of subtype H5N1 is one of the possible means to protect chickens against its outbreak in endemic countries. Early vaccination of layer birds with recombinant vector vaccine based on turkey herpesvirus expressing H5 gene (rHVT-H5) provides longer protection while inactivated vaccine Re-6 needs multiple booster doses to achieve continuous antibody titer. Therefore, this study was carried out to offer a vaccination program using live rHVT-H5 and inactivated Re-6 vaccines in field condition. For this trial, five ISA brown commercial layer chicken farms were raised with 500 birds per farm. Two licensed vaccines- rHVT-H5 and Re-6 in Bangladesh were used for this trial where birds in farms 1 and 2 were administered only rHVT-H5 vaccine at one-day-old, and farms 3 and 4 rHVT-H5 vaccine at one-day-old then boosted with Re-6 vaccine at 25 weeks of age. Farm 5 was not vaccinated and functioned as control. Blood samples were randomly collected from 20 birds in each farm at 3-week interval from 2 weeks old till 65 weeks and harvested serum analyzed by haemagglutination inhibition (HI) test for antibodies against HPAIV H5N1. The titer of haemagglutination inhibiting antibodies against AIV H5N1 on farms 3 and 4 was considerably high and remained up to 65 weeks. However, in farm 1 and 2 there was decline in antibody titer after 56 weeks of age. This study demonstrated that the combined use of rHVT-H5 vaccine at one-day-old and Re-6 at 25 weeks of age enhanced a longer lasting protective antibody against circulating HPAIV H5N1 in commercial layer chickens in Bangladesh. Stamford Journal of Microbiology, Vol.10 (1) 2020: 9-11
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
rHVT-H5和Re-6疫苗联合应用于商业蛋鸡的有效禽流感疫苗接种计划
针对H5N1亚型高致病性禽流感病毒(HPAIV)的疫苗接种是在流行国家保护鸡免受其暴发的可能手段之一。以表达H5基因的火鸡疱疹病毒为基础的重组载体疫苗(rHVT-H5)早期接种蛋鸡具有较长的保护作用,而Re-6灭活疫苗需要多次加强才能达到连续的抗体滴度。因此,本研究旨在提供一种在野外条件下使用rHVT-H5活疫苗和Re-6灭活疫苗的接种方案。本试验在5个ISA棕色商业蛋鸡养殖场进行饲养,每个养殖场500只鸡。该试验使用了两种获得许可的疫苗——孟加拉国的rHVT-H5和Re-6疫苗,其中1号和2号农场的家禽在1日龄时仅接种rHVT-H5疫苗,3号和4号农场在1日龄时接种rHVT-H5疫苗,然后在25周龄时接种Re-6疫苗。5号农场没有接种疫苗,而是作为对照。从2周龄至65周龄,每隔3周随机采集20只家禽的血样,采集后的血清通过血凝抑制(HI)试验检测HPAIV H5N1抗体。3号和4号农场抗禽流感病毒H5N1的血凝抑制抗体滴度相当高,并持续到65周。然而,养殖场1和养殖场2在56周龄后抗体滴度下降。该研究表明,在1日龄和25周龄时联合使用rhrt - h5疫苗和Re-6疫苗,可增强孟加拉国商品蛋鸡对循环HPAIV H5N1的持久保护性抗体。微生物学杂志,Vol.10 (1) 2020: 9-11
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Incidence of Antibiotic Resistant Bacteria In Fish Sold In Local Market In Dhaka City Isolation of Indigenous Bacillus Spp. From Garden Soil To Decolorize Synthetic Textile Dyes Antibiogram Profiling of Clinical Isolates From Several Renowned Diagnostic Centers In Dhaka City, Bangladesh Antimicrobial Photodynamic Therapy (Apdt), An Approach To Fightback Against Antibiotic Resistance: A Short Review Mitigation of Heavy Metal Pollution-An Overview Of Microbial Remediation And Prospect In Bangladesh
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1